Danielle Miller

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

6

H-Index

1

About

Dr. Danielle Miller is a leading biotechnologist whose work focuses on the analytical characterization and quality control of next-generation mRNA therapeutics. Her primary research addresses the critical challenge of ensuring the safety and efficacy of mRNA vaccines by detecting and quantifying process-related impurities. Her most impactful contribution is the development and application of an automated Sandwich ELISA assay for quantitating residual double-stranded RNA (dsRNA) in mRNA vaccines. This work is foundational, as dsRNA is a known immunostimulatory impurity generated during in vitro transcription that can compromise vaccine potency and patient safety. Her 2024 paper on this method has already garnered 6 citations, highlighting its immediate relevance to the pharmaceutical industry. By providing a robust, high-throughput quality control tool, Dr. Miller’s research directly enables the scalable, safe manufacturing of mRNA vaccines, a technology now critical for confronting global disease. Her achievements place her at the forefront of ensuring the reliability of this revolutionary vaccine platform.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Development and Application of Automated Sandwich ELISA for Quantitating Residual dsRNA in mRNA Vaccines
6 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago